Drugs / human recombinant Bone Morphogenetic Protein 4
human recombinant Bone Morphogenetic Protein 4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02869243 | Jul 2017 → Oct 2020 | glioblastoma | Stemgen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human recombinant Bone Morphogenetic Protein 4 | “BACKGROUND: This Phase 1 study evaluates the intra- and peritumoral administration by convection enhanced delivery (CED) of human recombinant Bone Morphogenetic Protein 4...” PMID 37563568 ↗ Aug 2023 |
| Known as | hrBMP4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02869243 ↗ |
| Known as | R-hbmp4 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594551 ↗ |
| Action | Inhibit | “hrBMP4) - an inhibitory regulator of cancer stem cells (CSCs)” PMID 37563568 ↗ Aug 2023 |
| Modality | Protein / enzyme biologic | “human recombinant Bone Morphogenetic Protein 4 (hrBMP4)” PMID 37563568 ↗ Aug 2023 |
| Route | Other | “intra- and peritumoral administration by convection enhanced delivery (CED)” PMID 37563568 ↗ Aug 2023 |